Literature DB >> 10075822

A scintillation proximity assay for the Raf/MEK/ERK kinase cascade: high-throughput screening and identification of selective enzyme inhibitors.

O B McDonald1, W J Chen, B Ellis, C Hoffman, L Overton, M Rink, A Smith, C J Marshall, E R Wood.   

Abstract

We have developed a quantitative scintillation proximity assay (SPA) that reproduces the Raf/MEK/ERK signal transduction pathway. The components of this assay include human cRaf1, MEK1, and ERK2 and a biotinylated peptide substrate for ERK2. cRaf1 was expressed as a his-tagged protein in insect cells in an active form. MEK1 and ERK2 were expressed in Escherichia coli as glutathione S-transferase (GST)-fusion proteins in their inactive forms. ERK2 was removed from the GST portion of the fusion protein by cleavage with thrombin protease. When the purified components are incubated together, cRaf-1 phosphorylates and activates MEK1, MEK1 phosphorylates and activates ERK2, and ERK2 phosphorylates the peptide, biotin-AAATGPLSPGPFA. Phosphorylation of the peptide using [gamma-33P]ATP is detected following binding to streptavidin-coated SPA beads. The assay detects inhibitors of cRaf1, MEK1, or ERK2, and has been used to screen large numbers of compounds. The specific target of inhibition was subsequently identified with secondary assays described herein. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10075822     DOI: 10.1006/abio.1998.3030

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  10 in total

1.  Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An update.

Authors:  Angela Gauthier; Mitchell Ho
Journal:  Hepatol Res       Date:  2012-11-12       Impact factor: 4.288

2.  Molecular characteristics of CTA056, a novel interleukin-2-inducible T-cell kinase inhibitor that selectively targets malignant T cells and modulates oncomirs.

Authors:  Wenchang Guo; Ruiwu Liu; Yoko Ono; Ai-Hong Ma; Anthony Martinez; Eduardo Sanchez; Yan Wang; Wenzhe Huang; Anisha Mazloom; Jixian Li; Jinying Ning; Emanual Maverakis; Kit S Lam; Hsing-Jien Kung
Journal:  Mol Pharmacol       Date:  2012-08-16       Impact factor: 4.436

3.  Expressed in the yeast Saccharomyces cerevisiae, human ERK5 is a client of the Hsp90 chaperone that complements loss of the Slt2p (Mpk1p) cell integrity stress-activated protein kinase.

Authors:  Andrew W Truman; Stefan H Millson; James M Nuttall; Victoria King; Mehdi Mollapour; Chrisostomos Prodromou; Laurence H Pearl; Peter W Piper
Journal:  Eukaryot Cell       Date:  2006-09-01

4.  Fluorescent cascade and direct assays for characterization of RAF signaling pathway inhibitors.

Authors:  Kevin R Kupcho; Rica Bruinsma; Tina M Hallis; David A Lasky; Richard L Somberg; Tammy Turek-Etienne; Kurt W Vogel; Kristin G Huwiler
Journal:  Curr Chem Genomics       Date:  2008-02-25

5.  Discovery of potent, orally active compounds of tyrosine kinase and serine/threonine-protein kinase inhibitor with anti-tumor activity in preclinical assays.

Authors:  Yun-Qing Qiu; Jue Zhou; Xin-Shan Kang; Jian-Zhong Shen-Tu; Lie-Ming Ding; Fen-Lai Tan; Jing Guo; Lan-Juan Li
Journal:  Afr J Tradit Complement Altern Med       Date:  2012-04-02

6.  Phosphatase-coupled universal kinase assay and kinetics for first-order-rate coupling reaction.

Authors:  Zhengliang L Wu
Journal:  PLoS One       Date:  2011-08-11       Impact factor: 3.240

7.  Targeting Btk/Etk of prostate cancer cells by a novel dual inhibitor.

Authors:  W Guo; R Liu; G Bhardwaj; J C Yang; C Changou; A-H Ma; A Mazloom; S Chintapalli; K Xiao; W Xiao; P Kumaresan; E Sanchez; C-T Yeh; C P Evans; R Patterson; K S Lam; H-J Kung
Journal:  Cell Death Dis       Date:  2014-09-04       Impact factor: 8.469

8.  Recombinant Peptide Production Platform Coupled with Site-Specific Albumin Conjugation Enables a Convenient Production of Long-Acting Therapeutic Peptide.

Authors:  Mijeong Bak; Junyong Park; Kiyoon Min; Jinhwan Cho; Jihyoun Seong; Young S Hahn; Giyoong Tae; Inchan Kwon
Journal:  Pharmaceutics       Date:  2020-04-16       Impact factor: 6.321

9.  Comparative expression of soluble, active human kinases in specialized bacterial strains.

Authors:  Allison Sunderhaus; Ramsha Imran; Elanzou Enoh; Adesola Adedeji; Taiye Obafemi; May H Abdel Aziz
Journal:  PLoS One       Date:  2022-04-19       Impact factor: 3.240

10.  CTA095, a novel Etk and Src dual inhibitor, induces apoptosis in prostate cancer cells and overcomes resistance to Src inhibitors.

Authors:  Wenchang Guo; Ruiwu Liu; Gaurav Bhardwaj; Ai-Hong Ma; Chun Changou; Joy C Yang; Yuanpei Li; Caihong Feng; Yan Luo; Anisha Mazloom; Eduardo Sanchez; Yan Wang; Wenzhe Huang; Randen Patterson; Christopher P Evans; Kit S Lam; Hsing-Jien Kung
Journal:  PLoS One       Date:  2013-08-15       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.